|
Dr. Olukotun joined the Icagen Board in August 2006. Dr. Olukotun is a board certified cardiologist and has more than twenty-five years of experience in clinical research and drug development in the pharmaceutical and biotechnology industry. Dr. Olukotun has been the Chief Medical Officer of VIA Pharmaceuticals since July 2004. Prior to joining VIA Pharmaceuticals Dr. Olukotun founded CR Strategies LLC a clinical research and development consulting firm in Princeton NJ and served as its Chief Executive Officer from 2000 to 2003. Dr. Olukotun also served as the Chief Medical Officer of Esperion Therapeutics Inc. a cardiovascular drug development company from July 2001 until its acquisition by Pfizer in April 2004. From June 1996 to January 2001 Dr. Olukotun was Vice President of Medical and Regulatory Affairs and Chief Medical Officer of Mallinckrodt Inc. Prior to joining Mallinckrodt Dr. Olukotun spent thirteen years at Bristol-Myers Squibb Company where he served as Vice President of two divisions focused on cardiovascular research and was involved in the clinical development of several cardiovascular and lipid-regulating agents.
Dr. Olukotun received his M.D. degree from Albert Einstein College of Medicine and obtained a MPH degree from Harvard University School of Public Health and is a Fellow of the American College of Cardiology. | 